Cyclophosphamide and bone

Cyclophosphamide is a chemotherapy drug used for certain cancers and some autoimmune conditions. Like many chemotherapy agents, it can affect bone health indirectly, mainly by disrupting the hormones that normally keep bone remodeling in balance. In women, it can push the ovaries into early menopause, dropping estrogen levels. In men, it can lower testosterone. Both of these hormone drops speed up bone loss, because estrogen and testosterone normally help keep bone-removing cells (osteoclasts) in check.

People being treated with cyclophosphamide are often also on corticosteroids or other immune-suppressing drugs, which independently harm bone. This combination means bone loss during cancer or autoimmune treatment is usually caused by several overlapping factors, not the chemotherapy alone. Reduced physical activity during treatment, poor appetite, and low vitamin D can add to the problem.

Because of this, doctors sometimes monitor bone density with a DEXA scan before, during, or after cyclophosphamide treatment, especially if other risk factors are present. If bone loss is found, your prescriber may discuss options such as calcium and vitamin D status, weight-bearing exercise as tolerated, or bone-specific medications. Any decisions about starting, stopping, or adjusting treatment should always be made with your oncologist or prescribing doctor, who can weigh the cancer treatment goals against bone health.